Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Long-acting beta-agonists open the airways by relaxing smooth muscle around the airways. They do not decrease inflammation of pulmonary tissues and are often used with inhaled steroids as a long-term control medication to open the airways in people with moderate to severe asthma.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

<table>
<thead>
<tr>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Serevent® Diskus®</td>
<td>• Arcapta® Neohaler®</td>
</tr>
<tr>
<td></td>
<td>• Arformoterol</td>
</tr>
<tr>
<td></td>
<td>• Brovana®</td>
</tr>
<tr>
<td></td>
<td>• Formoterol</td>
</tr>
<tr>
<td></td>
<td>• Perforomist®</td>
</tr>
<tr>
<td></td>
<td>• Striverdi® Respimat®</td>
</tr>
</tbody>
</table>

Type of Criteria: ☒ Preferred Drug List

Data Sources: ☒ Databases + Prescriber-Supplied

Setting & Population

• Drug class for review: Beta Adrenergic Agents, Long Acting
• Age range: All appropriate MO HealthNet participants

Approval Criteria

• Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
  o Documented trial period of preferred agent
  o Documented ADE/ADR to preferred agent
Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Lack of adequate trial on required preferred agent

Required Documentation

<table>
<thead>
<tr>
<th>Laboratory Results:</th>
<th>Progress Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedWatch Form:</td>
<td>Other:</td>
</tr>
</tbody>
</table>

Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.